Discount Agreements for Vilanterol and Fluticasone Furoate
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Vilanterol und Fluticasonfuroat, ATC R03AK10
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
The open-house model is not subject to public procurement law. Legal remedies are through social courts, not procuremen...
No guaranteed minimum volume or value; the contract is non-exclusive and may be superseded by other rebate contracts.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Apr 2027
- Non-exclusive rebate agreements for pharmaceuticals containing Vilanterol and Fluticasone furoate (ATC R03AK10)
- Open-house model (not a competitive procurement)
Show full summary
Non-exclusive open-house rebate agreement for the active substance Vilanterol and Fluticasone furoate (ATC R03AK10) with AOK Bayern. All eligible pharmaceutical companies can join under identical non-negotiable terms. Contract term from 01.05.2025 to 30.04.2027, with possibility of early termination. The procedure is not a public procurement but a permitted open-house model.
Risks
The open-house model is not subject to public procurement law. Legal remedies are through social courts, not procuremen...
No guaranteed minimum volume or value; the contract is non-exclusive and may be superseded by other rebate contracts.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible as potential contractors.
Administrative
- Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
- Contract and annex must be signed and submitted in paper (two copies) with handwritten signature or electronically with qualified electronic signature.
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Discount Agreements for Vilanterol and Fluticasone Furoate
Open-house model for discount agreements on pharmaceuticals containing Vilanterol and Fluticasone furoate. All interested pharmaceutical companies that meet the eligibility criteria may conclude identical non-exclusive rebate agreements.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Vilanterol und Fluticasonfuroat, ATC R03AK10
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 18 Mar 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 178616-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
The open-house model is not subject to public procurement law. Legal remedies are through social courts, not procuremen...
No guaranteed minimum volume or value; the contract is non-exclusive and may be superseded by other rebate contracts.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications